ORION CLASS B news, videos and press releases
For more news please use our advanced search feature.
ORION CLASS B - More news...
ORION CLASS B - More news...
- CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel
- Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel
- Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics
- Penalty payment to a member of Orion’s Board of Directors for delay in notifying managers’ transaction
- 142,701 Orion Corporation A shares converted into B shares
- Orion Research Foundation grants EUR 1,109,000 for research in 2025
- Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies
- Orion Corporation: Managers’ transactions – Henrik Stenqvist
- Orion Group Interim Report January–September 2024
- Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule
- Orion publishes Interim Report for January–September 2024 and holds a webcast on 29 October 2024
- Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU
- Orion’s near-term climate targets approved by the Science Based Targets initiative
- Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster
- Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology
- 213,285 Orion Corporation A shares converted into B shares
- Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer
- Inside information: Orion upgrades full-year outlook for 2024
- Orion Corporation: Managers’ transactions – Satu Ahomäki
- Orion Corporation: Managers’ transactions – Niclas Lindstedt
- Orion Corporation: Managers’ transactions – Liisa Hurme
- Orion Corporation: Managers’ transactions – Hao Pan
- 44,767 Orion Corporation A shares converted into B shares
- Orion Corporation: Managers’ transactions – Satu Ahomäki
- Orion Group Half-Year Financial Report January–June 2024
- Orion Corporation’s financial reporting and Annual General Meeting in 2025
- Orion publishes Half-Year Financial Report for January–June 2024 and holds a webcast on 8 August 2024
- Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint
- Inside information: Orion upgrades full-year outlook for 2024
- Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
